HEOR · Market Access · AI

NullHypo.

Built on the work. Not about it.

Articles on health economic modelling, evidence synthesis, biostatistics, market access, and AI in pharma.

Who builds this

Shubhram Pandey is an HEOR and Market Access professional with deep hands-on experience across health economic modelling, statistical analysis, evidence synthesis, and HTA submissions. For the last few years, building and stress-testing AI pipelines for the same work. Every claim on NullHypo is tested like a hypothesis.

Shubhram Pandey Follow on LinkedIn →

What we cover

Six domains.

Domain 01

Evidence Synthesis

Systematic literature reviews, network meta-analyses, indirect treatment comparisons, and MAICs. The methods, the assumptions behind them, and where automation genuinely earns its place.

Domain 02

Real-World Evidence & Biostatistics

Clinical trial analysis, RWE from EHR and claims databases, PRO analysis, and survival analysis. Statistical rigour stays non-negotiable, whatever the tooling.

Domain 03

Health Economic Modelling

Markov, partitioned survival, and patient-level simulation. Model conceptualisation, development, and validation, from early decision-analytic frameworks to submission-ready models.

Domain 04

HTA Evidence & Submissions

Dossier development and submission strategy for NICE, CADTH, EU-HTA, and global HTA bodies. What robust evidence assembly looks like in a regulatory context.

Domain 05

Market Access Strategy

Payer intelligence, HTA signal interpretation, and value story development for the decisions that directly affect reimbursement outcomes.

Domain 06

AI, Prompting & Pipelines

Practical prompting techniques, tool benchmarks tested on real HEOR tasks, and end-to-end pipeline builds, with the architecture, the code, and the failure modes.